US 2023/0212253 A1Published application

Methods of obtaining tumor-specific t cell receptors

AssigneesSYZ Cell Therapy Co., Hryz Biotech Co.

InventorsXiangjun ZHOU, Yanyan HAN, Xihe CHEN

Life of this patent

Estimating the term…

Abstract

Provided methods of obtaining a plurality of T cell receptors specifically recognizing a target tumor antigen peptide from an individual that has clinically benefitted from an immunotherapy, such as Multiple Antigen Specific Cell Therapy. Also provided tumor-specific TCRs, engineered immune cells expressing the TCRs and methods of treating a disease using the engineered immune cells.

Claims18

Dependent claims

A tumor-specific TCR comprising an antigen binding domain that binds to an epitope of HPV18-E7 comprising the amino acid sequence of SEQ ID NO:

85, wherein the TCR is selected from the group consisting of the following TCRs:
(a) a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
274, a CDR2 comprising the amino acid sequence of SEQ ID NO:
275, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
58;
and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
276, a CDR2 comprising the amino acid sequence of SEQ ID NO:
277, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
61;
(b) a TCRα chain comprising a CDR1 comprising amino acid residues 27 to 38 of SEQ ID NO:
65, a CDR2 comprising amino acid residues 56 to 65 of SEQ ID NO:
65, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
64, and a TCRβ chain comprising a CDR1 comprising amino acid residues 27 to 38 of SEQ ID NO:
68, a CDR2 comprising amino acid residues 56 to 65 of SEQ ID NO:
68, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
67;
(c) a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
278, a CDR2 comprising the amino acid sequence of SEQ ID NO:
279, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
70;
and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
280, a CDR2 comprising the amino acid sequence of SEQ ID NO:
281, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
73;
(d) a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
282, a CDR2 comprising the amino acid sequence of SEQ ID NO:
283, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
76;
and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
284, a CDR2 comprising the amino acid sequence of SEQ ID NO:
285, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
79;
(e) a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
286, a CDR2 comprising the amino acid sequence of SEQ ID NO:
287, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
87;
and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
288, a CDR2 comprising the amino acid sequence of SEQ ID NO:
289, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
90;
and
(f) a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
290, a CDR2 comprising the amino acid sequence of SEQ ID NO:
291, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
93;
and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
292, a CDR2 comprising the amino acid sequence of SEQ ID NO:
293, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
96.

46 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/843,920Filed 17 Jun 2022
Priority: WO PCT/CN2018/08294713 Apr 2018
Published: 6 Jul 2023
Term ends: Not estimatedThe source records don’t support an estimate.

Classification34 codes

C07K 14/7051
Immunoglobulin superfamily: t-cell receptor -CD3 complex
A61K 39/12
Medicinal preparations containing antigens or antibodies: viral antigens
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…
A61K 40/19
Characterised by the cell type used: dendritic cells

Family

Application17/047,059Division · filed 12 Oct 2020
Application17/843,920Division
US 11,390,659 B2Related patent
US 2021/0198341 A1Published application
US 2023/0212253 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

A tumor-specific TCR comprising an antigen binding domain that binds to an epitope of HPV18-E7 comprising the amino acid sequence of SEQ ID NO:

85, wherein the TCR is selected from the group consisting of the following TCRs:
(a) a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
274, a CDR2 comprising the amino acid sequence of SEQ ID NO:
275, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
58;
and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
276, a CDR2 comprising the amino acid sequence of SEQ ID NO:
277, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
61;
(b) a TCRα chain comprising a CDR1 comprising amino acid residues 27 to 38 of SEQ ID NO:
65, a CDR2 comprising amino acid residues 56 to 65 of SEQ ID NO:
65, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
64, and a TCRβ chain comprising a CDR1 comprising amino acid residues 27 to 38 of SEQ ID NO:
68, a CDR2 comprising amino acid residues 56 to 65 of SEQ ID NO:
68, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
67;
(c) a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
278, a CDR2 comprising the amino acid sequence of SEQ ID NO:
279, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
70;
and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
280, a CDR2 comprising the amino acid sequence of SEQ ID NO:
281, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
73;
(d) a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
282, a CDR2 comprising the amino acid sequence of SEQ ID NO:
283, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
76;
and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
284, a CDR2 comprising the amino acid sequence of SEQ ID NO:
285, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
79;
(e) a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
286, a CDR2 comprising the amino acid sequence of SEQ ID NO:
287, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
87;
and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
288, a CDR2 comprising the amino acid sequence of SEQ ID NO:
289, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
90;
and
(f) a TCRα chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
290, a CDR2 comprising the amino acid sequence of SEQ ID NO:
291, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
93;
and a TCRβ chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
292, a CDR2 comprising the amino acid sequence of SEQ ID NO:
293, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
96.

46 more elements

Facts

Application

17/843,920Filed 17 Jun 2022

Priority

WO PCT/CN2018/08294713 Apr 2018

Published

6 Jul 2023

Term ends

Not estimatedThe source records don’t support an estimate.

Classification34 codes

C07K 14/7051
Immunoglobulin superfamily: t-cell receptor -CD3 complex
A61K 39/12
Medicinal preparations containing antigens or antibodies: viral antigens
A61K 40/11
Characterised by the cell type used: t-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer…
A61K 40/19
Characterised by the cell type used: dendritic cells